← FDA DRUG APPROVALS

FDA ANDA · ANDA200541

TRI-LO-MARZIA

norgestimate and ethinyl estradiol

Sponsor: LUPIN PHARMS

APPLICATION
ANDA200541
TYPE
ANDA
ORIGINAL APPROVAL
2012-06-25
LATEST ACTION
2022-04-29
ROUTE
ORAL-28
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

NORGESTIMATE AND ETHINYL ESTRADIOLPrescription
ETHINYL ESTRADIOL 0.025MG,0.025MG,0.025MG, NORGESTIMATE 0.18MG,0.215MG,0.25MG · TABLET · ORAL-28

Approval history

2022-04-29Labeling · Supplement 12 · standardAP
2019-01-28Labeling · Supplement 5 · standardAP
2019-01-28Manufacturing (CMC) · Supplement 8 · unknownAP
2012-09-26Labeling · Supplement 1 · standardAP
2012-06-25Not Applicable · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →